Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
5 Year Post-Approval Study With the REALIZE (TM) Adjustable Gastric Band
This study is currently recruiting participants.
Verified by Ethicon Endo-Surgery, December 2008
Sponsored by: Ethicon Endo-Surgery
Information provided by: Ethicon Endo-Surgery
ClinicalTrials.gov Identifier: NCT00813462
  Purpose

To determine the re-operation rate (band revision, band replacement and explants resulting from serious adverse device-related event {SADE}) of gastric banding at 4 and 5 year post implant.


Condition Intervention Phase
Morbid Obesity
Device: REALIZE™ Adjustable Gastric Band
Phase IV

MedlinePlus related topics: Obesity
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Open Label, Single Group Assignment, Safety Study
Official Title: 5 Year Post-Approval Study With the REALIZE™ Adjustable Gastric Band

Further study details as provided by Ethicon Endo-Surgery:

Primary Outcome Measures:
  • To determine the re-operation rate (band revision, band replacement and explants resulting from serious adverse device-related event {SADE})of gastric banding at 4 and 5 years post implant. [ Time Frame: 2014 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluate changes in excess body weight at 4 and 5 years post-implant. [ Time Frame: 2014 ] [ Designated as safety issue: No ]
  • To evaluate changes in Quality of Life measures and 4 and 5 years post implant. [ Time Frame: 2014 ] [ Designated as safety issue: No ]
  • To evaluate changes in Glycosylated hemoglobin (HbA1c) and serum lipid levels at 4 and 5 years post implant. [ Time Frame: 2014 ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: December 2008
Estimated Study Completion Date: January 2014
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: REALIZE™ Adjustable Gastric Band
    Laparascopic Placement of the REALIZE™ Adjustable Gastric Band
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects eligible to participate in this study must fulfill all of the following criteria:

    1. Able to comprehend, follow and give informed consent;
    2. 18 to 60 years of age (inclusive);
    3. Body Mass Index (BMI) of > 40 kg/m2 and £ 55 kg/m2, or BMI ³ 35 kg/m2 and < 40 kg/m2 with one or more co-morbid conditions.
    4. Candidate for surgical weight loss intervention in accordance with the Instructions For Use (i.e., meets acceptable health criteria for major surgery).

Exclusion Criteria:

  1. Women who are currently pregnant.
  2. Previous malabsorptive or restrictive procedures performed for the treatment of morbid obesity.
  3. Documented history of drug and/or alcohol abuse within 2 years of the Screening Visit (1a).
  4. Presence of any of the following medical conditions;

    1. Inflammatory diseases of the gastrointestinal tract, including severe intractable esophagitis, gastric ulceration or duodenal ulceration, or specific inflammation such as Crohn's disease;
    2. Severe cardiopulmonary disease or other serious organic disease;
    3. Upper gastrointestinal bleeding conditions such as esophageal or gastric varices or intestinal telangiectases;
    4. Portal hypertension;
    5. Anomalies of the gastrointestinal tract such as atresia or stenosis;
    6. Cirrhosis of the liver;
    7. Chronic pancreatitis;
    8. Patients on chronic, long-term steroid treatment or steroids within 15 days of surgery;
    9. Unable or unwilling to comply with dietary restrictions required by this procedure;
    10. Known allergy to materials contained within the band or its injection port (silicone elastomer containing 10% BaSO4, polyetheretherketone (PEEK), and cobalt chromium)
  5. Presence of terminal illness with life expectancy of £ 5 years.
  6. Inability to refrain from use of antigoagulants or aspirin within 15 days prior to surgery.
  7. Acute or chronic infection (localized or systemic).
  8. Participation in another clinical trial within 8 weeks of the Screening Visit (1a) and for the duration of this trial.
  9. Any medical condition or finding for which the Investigator utilizes their medical discretion to determine the subject should be excluded due to inability to understand or follow study procedures.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00813462

Locations
United States, California
Sunil Bhoyrul, MD Recruiting
La Jolla, California, United States, 92037
Contact: Simpson     858-452-5054        
United States, Florida
Robert T. Marema, MD Recruiting
St. Augustine, Florida, United States, 32086
Contact: Marema     904-819-5861        
Sponsors and Collaborators
Ethicon Endo-Surgery
  More Information

Responsible Party: Ethicon Endo-Surgery, Inc ( Sheryl Helsinger )
Study ID Numbers: CI-07-0006
Study First Received: December 22, 2008
Last Updated: December 22, 2008
ClinicalTrials.gov Identifier: NCT00813462  
Health Authority: United States: Institutional Review Board

Study placed in the following topic categories:
Body Weight
Signs and Symptoms
Obesity
Nutrition Disorders
Overweight
Overnutrition
Obesity, Morbid

ClinicalTrials.gov processed this record on January 13, 2009